Category: ~$3.3B

  • Novo Nordisk to Acquire Dicerna for ~$3.3B

    Shots: Novo Nordisk to acquire all outstanding shares of Dicerna common stock for $38.25/share in cash making a total equity value of ~$3.3B representing a premium of 80% to Dicerna’s closing price on Nov 17, 2021. The transaction is expected to close in the Q4’21 The acquisition will utilize Dicerna’s GalXC technology platform to expand […]